David Foehr Sells 987 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 987 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total value of $17,766.00. Following the sale, the vice president directly owned 38,613 shares of the company’s stock, valued at $695,034. The trade was a 2.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Friday, May 22nd, David Foehr sold 862 shares of CeriBell stock. The shares were sold at an average price of $18.80, for a total value of $16,205.60.
• On Tuesday, March 3rd, David Foehr sold 4,560 shares of CeriBell stock. The shares were sold at an average price of $17.80, for a total value of $81,168.00.

CeriBell Stock Performance

Shares of CBLL opened at $18.70 on Thursday. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $709.48 million, a price-to-earnings ratio of -11.47 and a beta of 0.99. The stock has a 50 day moving average of $19.08 and a 200 day moving average of $19.29. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $24.33.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The business had revenue of $26.49 million for the quarter, compared to analysts’ expectations of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. As a group, sell-side analysts forecast that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Institutional Trading of CeriBell

A number of large investors have recently bought and sold shares of the company. Bank of America Corp DE increased its position in CeriBell by 15.3% in the first quarter. Bank of America Corp DE now owns 319,837 shares of the company’s stock worth $5,863,000 after buying an additional 42,340 shares during the last quarter. Quantinno Capital Management LP increased its position in CeriBell by 3.0% in the first quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock worth $2,573,000 after buying an additional 4,119 shares during the last quarter. Sei Investments Co. increased its position in CeriBell by 2.3% in the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after buying an additional 1,125 shares during the last quarter. State of Wyoming bought a new position in shares of CeriBell in the first quarter worth $62,000. Finally, KCM Capital Inc boosted its holdings in shares of CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after acquiring an additional 400,000 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. BTIG Research reissued a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. Canaccord Genuity Group decreased their target price on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Finally, Weiss Ratings downgraded CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, CeriBell has an average rating of “Moderate Buy” and a consensus price target of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.